Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Cladribine (Mavenclad -- EMD Serono) indication: relapsing-remitting multiple sclerosis

The CADTH Canadian Drug Expert Committee recommends that cladribine be reimbursed as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, October 2018
Edition:Version: Final
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Cladribine / Therapeutic Use
Multiple Sclerosis, Relapsing-remitting / Drug Therapy
Canada
Cladribine / Economics
Cost-benefit Analysis
Treatment Outcome
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee recommends that cladribine be reimbursed as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability
Physical Description:1 PDF file (8 pages)

Similar Items